Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation.
作者信息
Salazar Jonathan A, Goldsmith Jeffrey D, Bousvaros Athos, Tracy Michaela
机构信息
Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Gastroenterol Hepatol (N Y). 2024 Oct;20(9):546-549.
Abstract
摘要
相似文献
1
Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation.溃疡性结肠炎患者在开始使用乌帕替尼后出现巨细胞病毒性结肠炎且皮质类固醇反应丧失。
Gastroenterol Hepatol (N Y). 2024 Oct;20(9):546-549.
2
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.一名患有严重难治性溃疡性结肠炎患者的巨细胞病毒性结肠炎
Crohns Colitis 360. 2024 Feb 28;6(1):otae014. doi: 10.1093/crocol/otae014. eCollection 2024 Jan.
3
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.在溃疡性结肠炎患者中，基线皮质类固醇使用对 upadacitinib 疗效和安全性的影响：III 期临床试验计划的事后分析。
J Crohns Colitis. 2024 May 31;18(5):695-707. doi: 10.1093/ecco-jcc/jjad190.
4
Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study.中国单中心研究：乌帕替尼治疗急性重度溃疡性结肠炎患者的疗效和安全性。
Clin Exp Med. 2024 Sep 30;24(1):233. doi: 10.1007/s10238-024-01468-z.
5
The role of upadacitinib in the treatment of ulcerative colitis.乌帕替尼在溃疡性结肠炎治疗中的作用。
Immunotherapy. 2023 Jul;15(10):713-727. doi: 10.2217/imt-2022-0299. Epub 2023 Apr 27.
6
Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.系统评价与荟萃分析：乌帕替尼在治疗中重度克罗恩病和溃疡性结肠炎的疗效和安全性。
Clin Drug Investig. 2024 Jun;44(6):371-385. doi: 10.1007/s40261-024-01364-0. Epub 2024 May 23.
7
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.乌帕替尼作为中度至重度活动溃疡性结肠炎的诱导和维持治疗：三项 3 期、多中心、双盲、随机临床试验的结果。
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
8
Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis.乌帕替尼 salvage 治疗英夫利昔单抗治疗经验的急性重度溃疡性结肠炎患者。
J Crohns Colitis. 2023 Dec 30;17(12):2033-2036. doi: 10.1093/ecco-jcc/jjad115.
9
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.对接受8周诱导治疗有反应的中度至重度活动性溃疡性结肠炎患者进行乌帕替尼维持治疗的疗效和安全性（U-ACHIEVE维持治疗）：随机、安慰剂对照、双盲3期维持研究的总体结果
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9.
10
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.在健康受试者和类风湿关节炎、克罗恩病、溃疡性结肠炎或特应性皮炎受试者中的乌帕替尼药代动力学：I 期和 II 期临床试验的群体分析。
J Clin Pharmacol. 2020 Apr;60(4):528-539. doi: 10.1002/jcph.1550. Epub 2019 Nov 7.
本文引用的文献
1
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.一名患有严重难治性溃疡性结肠炎患者的巨细胞病毒性结肠炎
Crohns Colitis 360. 2024 Feb 28;6(1):otae014. doi: 10.1093/crocol/otae014. eCollection 2024 Jan.
2
Cytomegalovirus Retinitis in a Patient Taking Upadacitinib: A Case Report.一名服用乌帕替尼患者的巨细胞病毒性视网膜炎：病例报告
Cureus. 2023 Nov 5;15(11):e48337. doi: 10.7759/cureus.48337. eCollection 2023 Nov.
3
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes.乌帕替尼治疗中度至重度活动性溃疡性结肠炎（UC）成人患者的临床评估：患者选择及报告的结果
Clin Exp Gastroenterol. 2023 Mar 7;16:21-28. doi: 10.2147/CEG.S367086. eCollection 2023.
4
JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.类风湿关节炎患者中JAK激酶抑制剂与水痘带状疱疹病毒感染。文献系统评价
Reumatol Clin (Engl Ed). 2022 Oct;18(8):453-458. doi: 10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.
5
JAK inhibitors and infections risk: focus on herpes zoster.JAK抑制剂与感染风险：聚焦带状疱疹
Ther Adv Musculoskelet Dis. 2020 Jun 29;12:1759720X20936059. doi: 10.1177/1759720X20936059. eCollection 2020.
6
Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.溃疡性结肠炎与巨细胞病毒感染：从 A 到 Z。
J Crohns Colitis. 2020 Sep 7;14(8):1162-1171. doi: 10.1093/ecco-jcc/jjaa036.
7
Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis.巨细胞病毒感染与炎症性肠病，尤其是激素抵抗性炎症性肠病有关吗？一项荟萃分析。
Infect Drug Resist. 2017 Dec 14;10:511-519. doi: 10.2147/IDR.S149784. eCollection 2017.
8
Alteration of glucocorticoid receptors and exacerbation of inflammation during lytic cytomegalovirus infection in THP-1 cells.巨细胞病毒溶解感染THP-1细胞期间糖皮质激素受体的改变及炎症加剧
FEBS Open Bio. 2017 Oct 30;7(12):1924-1931. doi: 10.1002/2211-5463.12334. eCollection 2017 Dec.
9
The Association Between CMV Viremia or Endoscopic Features and Histopathological Characteristics of CMV Colitis in Patients with Underlying Ulcerative Colitis.潜在溃疡性结肠炎患者中巨细胞病毒血症或内镜特征与巨细胞病毒结肠炎组织病理学特征之间的关联
Inflamm Bowel Dis. 2017 May;23(5):814-821. doi: 10.1097/MIB.0000000000001095.
10
Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.基于血液检测和组织病理学对炎症性肠病中巨细胞病毒再激活的诊断准确性：一项系统评价和荟萃分析
Inflamm Bowel Dis. 2017 Apr;23(4):551-560. doi: 10.1097/MIB.0000000000001073.
Zotero 插件